Androgen Receptor Inhibitor Drug Class List

Drugs in Drug Class: Androgen Receptor Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Adaptis	BICALUTAMIDE	bicalutamide	TABLET;ORAL	079089-001	Jul 6, 2009	AB	RX	No	No
Accord Hlthcare	BICALUTAMIDE	bicalutamide	TABLET;ORAL	078917-001	Jul 6, 2009	AB	RX	No	No
Sun Pharm	BICALUTAMIDE	bicalutamide	TABLET;ORAL	079110-001	Jul 6, 2009	AB	RX	No	No

Last updated: June 15, 2026

Market dynamics and patent landscape for androgen receptor inhibitor drugs

Androgen receptor (AR) inhibitors sit at the center of late-line metastatic castration-resistant prostate cancer (mCRPC) treatment and the broader AR-driven prostate cancer pipeline. Patents typically cluster around (i) small-molecule AR antagonists or CYP/transport metabolism, (ii) dosing regimens and treatment combinations, and (iii) formulation or crystal forms. Market access dynamics are increasingly driven by post-expiry generic entry risk, payer-driven sequencing, and ongoing patent estate “thickets” that extend exclusivity beyond first approval.

The AR inhibitor commercial field spans enzalutamide, apalutamide, darolutamide, and investigational or adjacent AR-pathway agents (including AR degraders). The patent landscape is still active because many core compounds reached market via 2010s approvals that are now nearing the end of composition-of-matter protection, while follow-on patents cover new salts, polymorphs, dosing, and combination indications.

Scope note

This analysis is limited to androgen receptor inhibitor small molecules used or pursued in prostate cancer and focuses on patent-driven exclusivity and generic/biosimilar entry risk mechanics that shape market dynamics for this class.

---

What patents protect androgen receptor inhibitor drugs used in prostate cancer?

Answer: The AR inhibitor patent estate is usually anchored by composition-of-matter filings on the active ingredient and extended by formulation, salt/polymorph, manufacturing, and method-of-use claims. Across the class, enforcement and market exclusivity typically rely on Orange Book-listed patents for approved uses plus unlisted patents for additional barriers (combos, dosing schedules, or manufacturing).

Core patent categories that dominate AR inhibitor estates

1. Composition of matter (active ingredient, salts, polymorphs)

   • Filed years before launch, typically the longest-lived.
   • Defines baseline barriers to generic substitution.

2. Method-of-use (treatment of mCRPC, combinations, patient subsets)

   • Captures line-of-therapy, timing, and combination logic (with ADT, chemotherapy, immunotherapy, radiopharmaceuticals).
   • Important where Orange Book coverage is incomplete.

3. Formulation and solid-state

   • Changes in salt form, crystal form, particle size, and excipient system can support follow-on protection.
   • Often relevant to “non-infringing design-around” strategies.

4. Manufacturing process

   • Process claims can block certain route-of-synthesis alternatives even if the compound is broadly known.

5. Dosing regimens

   • Sustained-release concepts and titration schedules are common in follow-on claims.

Typical assignees and patent holders (by brand lineage)

• Enzalutamide: anchored in patents tied to Medivation/its acquirers and later holders.
• Apalutamide and darolutamide: anchored in patents tied to Janssen/Arvinas and Bayer, depending on specific molecules and follow-on filings.
• Pipeline AR degraders and next-gen inhibitors: often held by specialist biotech or large pharma via acquisition.

(Brand-specific mapping depends on the exact Orange Book listings and expiration dates for each NDA, which define Paragraph IV and litigation timing.)

---

Which androgen receptor inhibitor patents drive Orange Book exclusivity and FDA listing status?

Answer: For most AR inhibitors, Orange Book exclusivity is driven by one or more compound-related patents and at least one set of formulation or method-of-use patents listed for each NDA. The listed patents dictate when generics can file Paragraph IV certifications and when litigation automatically triggers 30-month stays.

How Orange Book status translates into market timing

• Orange Book “patent term” clock: The relevant listed patent expiration date determines the earliest possible effective date for a generic entering as-of.
• Hatch-Waxman certification path:
  • If patents are “expired,” generic launch can occur sooner.
  • If patents are “not expired,” a Paragraph IV triggers litigation risk and a statutory stay.
• Exclusivity beyond patents:
  • Regulatory exclusivities (e.g., new chemical entity, pediatric exclusivity, data exclusivity) can extend market protection even when some patents expire, depending on the specific product.

Typical pattern in AR inhibitors

• One long-lived composition-of-matter patent expires first.
• Follow-on formulation/polymorph patents often expire later.
• Method-of-use claims may cover additional indications, sometimes supported by distinct listed patents or separate unlisted patents that still drive litigation.

---

When does androgen receptor inhibitor exclusivity end, and what are the generic launch scenarios?

Answer: Generic entry timing is governed by the earliest of: listed patent expiration dates, expiry of regulatory exclusivities, and resolution (or settlement) of Paragraph IV litigation. Launch typically occurs either (i) immediately upon the “last-to-expire” listed patent date, or (ii) earlier if a generic wins litigation or if a settlement authorizes launch at a defined date.

Generic launch scenario map (Hatch-Waxman mechanics)

1. No Paragraph IV filing before expiration

   • Generic launch possible after expiration of the last relevant Orange Book patent (and any applicable regulatory exclusivity).

2. Paragraph IV filed and generic loses

   • Statutory 30-month stay ends; generic launch stays barred unless appealed reversal or settlement changes terms.

3. Paragraph IV wins at trial or settlement allows early launch

   • Generic can launch at the agreed “carve-out” date.
   • In many AR inhibitor deals, settlements include patent-specific entry dates and sometimes non-infringement covenants for certain product variants.

Market dynamic in this class

AR inhibitors are often managed as interchangeable options in payer formularies based on net price after rebates. Even when generics launch, payer switching can be slower if clinicians perceive differential efficacy by subgroup or if manufacturers offer aggressive contracting.

---

How many patents cover each androgen receptor inhibitor, and how concentrated is the estate?

Answer: AR inhibitor estates are frequently concentrated around a limited number of family clusters that include multiple jurisdictions and follow-on patents. The number of Orange Book listings per product can be significant, but enforcement focus tends to narrow to the patents that are both (i) listed for the NDA and (ii) central to claim validity or product coverage.

What “high concentration” means commercially

• If a single patent family covers core compound or a key solid-state form, generics may face repeated litigation even if they clear one patent.
• If multiple families protect different claim theories (dose regimen vs solid-state vs use), settlements can become multi-variable, tying launch dates to multiple expiration events.

Why this matters for investors and licensors

• The probability-weighted timeline to generic entry improves when a generic can selectively attack the “last-to-expire” patents early.
• The probability-weighted timeline worsens when multiple late-expiring follow-ons remain unchallenged or are upheld on appeal.

---

What Paragraph IV challenges exist for androgen receptor inhibitor drugs, and how do they affect timing?

Answer: Paragraph IV challenges are the main mechanism by which generics test AR inhibitor patent estates before expiration. Outcomes are driven by (i) claim construction, (ii) prior art or obviousness defenses, and (iii) infringement proof tied to the accused formulation or dosing.

How Paragraph IV filings shape market dynamics

• Patent litigation triggers stay: A timely Paragraph IV filing imposes a 30-month FDA approval stay (subject to court findings).
• Settlement reshapes launch date: Many AR inhibitor disputes resolve via settlement, producing defined “entry windows” for generics.
• Design-around pressure: Generics may pursue different polymorphs or manufacturing routes to avoid solid-state or process claims.

Competitive landscape implication

If multiple generics file Paragraph IV on the same day or in the same window, the branded maker’s settlement strategy tends to become more aggressive to preserve pricing and avoid multiple launchers under different entry dates.

---

What patent litigation affects androgen receptor inhibitor drugs right now?

Answer: AR inhibitor litigation typically involves multi-patent cases in federal district courts where the brand asserts infringement of composition-of-matter, solid-state/formulation, and method-of-use claims. Cases often settle after claim construction or after summary judgment rulings narrow asserted claims.

Litigation patterns seen across the class

• Multi-forum reality: Brand holders coordinate with international patent families, but US litigation determines US launch.
• Appeals and re-litigation risk: Even after a first district court ruling, brand holders sometimes protect additional patents in parallel actions.
• Settlement-driven predictability: Many market participants rely on settlement schedules rather than court outcomes.

(Brand-specific case lists require the exact case docket data per NDA; this article template is class-level because it is not tied to a single NDA.)

---

What formulations are protected by androgen receptor inhibitor patents?

Answer: Formulation protection typically covers:

• specific salt forms,
• particular polymorphs or crystal morphologies,
• particle-size specifications,
• excipient and coating systems that change dissolution rate, bioavailability, or stability,
• manufacturing processes that yield the protected solid state.

Why formulation patents matter to generic entry

• Even if a generic replicates the active ingredient structure, an alternative solid form can reduce infringement risk.
• Conversely, if the brand’s formulation patents cover widely used production routes or commonly targeted particle specs, generics face higher process validation barriers.

Practical market implication

If the branded product’s bioequivalence is easy to achieve with multiple solid forms, formulation patents become weaker as a defense. If the formulation is tied to a specific solid-state critical quality attribute, formulation patents become a key gating factor for entry.

---

How do dosing regimen and method-of-use patents extend protection for androgen receptor inhibitors?

Answer: Method-of-use patents extend protection by defining protected therapeutic regimens, including:

• the combination partner (ADT, chemotherapy, immunotherapy),
• the sequencing (first-line vs later-line),
• the population (e.g., post-docetaxel mCRPC or specific biomarkers),
• dosing schedules or treatment duration.

Market effects

• Method-of-use patents can block generic labels even if the composition is non-problematic, delaying substitution.
• Payers may still switch based on “off-label” use, but in practice brand stays preferred where FDA labeling is constrained.

---

How does each androgen receptor inhibitor compare on patent expiry and market exposure?

Answer: Enzalutamide, apalutamide, and darolutamide each have different patent expiry profiles driven by their filing dates and follow-on families. Market exposure differs by:

• relative penetration in mCRPC lines,
• payer coverage and net pricing dynamics,
• availability of next-line therapies that reduce substitution urgency.

Comparative commercial structure (class-level)

• Enzalutamide: tends to have broader historic uptake across earlier and later mCRPC treatment settings; higher volume exposure increases the economic value of delayed generics.
• Apalutamide: widely used in non-metastatic CRPC and metastatic settings depending on indication expansion; broader franchise can increase settlement leverage.
• Darolutamide: often positioned with favorable tolerability; if penetration is smaller, the economic value of patent extension can still be high due to exclusivity-driven pricing stability.

(Exact “patent expiry ladders” require mapping each NDA’s Orange Book patents with expiration dates.)

---

Which companies are challenging the AR inhibitor patent estate, and what is their entry strategy?

Answer: Generic and biosimilar challengers typically employ a mix of early Paragraph IV filings and targeted invalidity arguments focused on prior art, obviousness, and non-infringement based on formulation differences.

Common entry strategies for small-molecule AR inhibitors

1. Attacking the “last-to-expire” Orange Book patents
2. Carving out or changing solid-state form
3. Challenging method-of-use scope by limiting label to unprotected indications
4. Settlement-first playbook
   • Accept authorized entry date in exchange for freedom to market without further infringement exposure.

Commercial impact

Even a “settlement win” often leaves brand holders with residual competitive pressure via branded-to-generic rebates, but it caps the upside of faster generic launches unless the last-to-expire dates are cleared.

---

What is the Orange Book status of androgen receptor inhibitor products?

Answer: Each branded AR inhibitor has an Orange Book listing set tied to its NDA(s) that includes:

• at least one active-ingredient related patent,
• multiple formulation/solid-state patents and/or method-of-use patents,
• a statutory exclusivity overlay for certain approval pathways.

What market participants use Operationally

• The earliest expiration among listed patents relevant to the generic certification.
• Whether a competitor’s Paragraph IV maps to “Orange Book” patents or tries to bypass them via label design.
• Whether settlements are “generic entry only” or also include product-specific restrictions.

---

How does the patent estate interact with the FDA pathway for AR inhibitors?

Answer: FDA approval pathway choice influences the timing of market entry but does not replace patent barriers. Generics for these small molecules typically use ANDA; follow-on 505(b)(2) can also appear for reformulations or new combinations, but patent coverage and exclusivity still apply.

Key FDA mechanics for market entry planning

• ANDA timing is driven by patent expiration and litigation status.
• 505(b)(2) can exploit new data or new formulation claims but cannot avoid patent infringement if a listed patent still covers the protected drug product.
• Labeling scope changes around method-of-use protection can determine whether substitution is immediate or delayed.

---

Key takeaways

• AR inhibitor markets are governed by a repeatable exclusivity playbook: composition-of-matter and solid-state/formulation follow-ons dominate, with method-of-use and dosing regimen claims extending practical barriers.
• Paragraph IV filings are the main lever for generics to force a litigation-based delay or an authorized settlement launch date.
• Orange Book-listed patents determine the legally operative timeline for ANDA entry in most cases; settlement terms often dictate the real-world launch schedule more than court outcomes.
• Formulation and solid-state patents create product-specific barriers that drive non-infringing design-around work and settlement complexity.
• Method-of-use patents can delay substitution through label design, even when composition claims are less enforceable.

---

FAQs

1) How do solid-state polymorph patents affect generic enzalutamide or apalutamide entry?

Solid-state claims can require the generic to match or avoid specific crystal forms and particle-size targets. If the brand’s manufacturing yields the protected solid state and infringement is provable, entry is delayed until design-around or settlement.

2) Can a generic enter AR inhibitor markets before the composition-of-matter patent expires?

Only if it clears the legally relevant Orange Book patents (including follow-on formulation or method-of-use listings), clears regulatory exclusivities for the specific product, or secures an authorized settlement that licenses launch before the “last-to-expire” date.

3) What role do combination method-of-use patents play in AR inhibitor substitution?

Combination regimen patents can restrict label-based substitution. Even if an ANDA is approved for the protected compound, the generic may be limited to unprotected uses, reducing immediate payer and prescriber switch.

4) What are the most common grounds for invalidating AR inhibitor patents in Paragraph IV cases?

Invalidity arguments typically include lack of novelty, obviousness, and anticipation using prior art; infringement defenses often center on differences in formulation, solid state, or dosing regimens.

5) How do payer contracting and rebates change the impact of AR inhibitor generic launches?

Even after legal entry, net price and formulary placement decide substitution pace. Branded makers often respond with rebate adjustments that can slow volume loss and extend the effective commercial life of the brand.

---

References

1. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”). U.S. Food and Drug Administration.
2. 35 U.S.C. § 271(e) and Hatch-Waxman provisions (Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act). U.S. Code.
3. FDA. ANDA and 505(b)(2) approval pathways overview. U.S. Food and Drug Administration.